Jack Allen
Stock Analyst at Baird
(1.02)
# 3,550
Out of 4,712 analysts
42
Total ratings
32.35%
Success rate
-16.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.46 | +117.25% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $8 → $4 | $0.58 | +595.65% | 2 | Nov 15, 2024 | |
| VOR Vor Biopharma | Maintains: Outperform | $22 → $14 | $1.27 | +1,002.36% | 3 | Nov 8, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $79.08 | +34.04% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $11.97 | +50.38% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $20.05 | +797.76% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $140 → $120 | $8.78 | +1,266.74% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $3.73 | +114.48% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $40.02 | +29.94% | 2 | May 9, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $29.18 | +187.87% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $1.75 | +357.14% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $2.19 | +447.95% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.50 | +906.04% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $1.61 | +1,639.13% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.41 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $5.74 | +56.79% | 1 | Oct 7, 2021 |
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.46
Upside: +117.25%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $8 → $4
Current: $0.58
Upside: +595.65%
Vor Biopharma
Nov 8, 2024
Maintains: Outperform
Price Target: $22 → $14
Current: $1.27
Upside: +1,002.36%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $79.08
Upside: +34.04%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $11.97
Upside: +50.38%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $20.05
Upside: +797.76%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $140 → $120
Current: $8.78
Upside: +1,266.74%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $3.73
Upside: +114.48%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $40.02
Upside: +29.94%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $29.18
Upside: +187.87%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $1.75
Upside: +357.14%
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $2.19
Upside: +447.95%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.50
Upside: +906.04%
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $1.61
Upside: +1,639.13%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.41
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $5.74
Upside: +56.79%